Altimmune (NASDAQ: ALT) Faces Legal Action After Pemvidutide Trial Results Fail to Impress

Altimmune Faces Legal Scrutiny Over Pemvidutide Trial Results

Altimmune, Inc. (NASDAQ: ALT) is currently navigating a challenging landscape as it confronts legal actions stemming from disappointing results of its Phase 2b MASH trial for its drug candidate, Pemvidutide. Following the announcement of trial results on June 26, 2025, which revealed that the primary endpoint for fibrosis reduction failed to achieve statistical significance, the company experiences a dramatic stock price decline, with shares plummeting from $7.71 to $3.61 in a single day. This significant downturn has prompted multiple law firms to issue notices to shareholders, encouraging them to join potential class action lawsuits regarding allegations of misleading statements made by the company prior to the trial results.

The Gross Law Firm and the Schall Law Firm are leading the charge, both asserting that Altimmune misrepresented the efficacy of Pemvidutide during the lead-up to the trial outcomes. Specifically, the firms argue that the company downplayed the trial's shortcomings while maintaining an optimistic outlook for future Phase 3 trials. This perceived misrepresentation has led to claims that investors were misled about the drug’s potential, ultimately resulting in substantial financial losses once the unfavorable results were disclosed. Shareholders who purchased Altimmune securities between August 10, 2023, and June 25, 2025, are particularly encouraged to register for participation in these lawsuits.

The implications of these legal actions extend beyond immediate financial consequences for Altimmune. They serve as a critical reminder of the importance of corporate transparency, particularly in the biopharmaceutical sector, where trial results can significantly impact investor confidence and stock valuations. As the case develops, Altimmune’s commitment to ethical business practices and transparent communication will be put to the test, as the company seeks to rebuild trust with its investors and stakeholders.

As Altimmune grapples with the fallout from the MASH trial results, the company remains under scrutiny from both shareholders and legal entities. The Gross Law Firm emphasizes that participation in the class action incurs no costs or obligations for investors, while the Schall Law Firm provides free consultations to affected shareholders. Both firms aim to hold Altimmune accountable for any alleged misrepresentation that may have inflated stock prices prior to the trial results, reinforcing the critical need for integrity in corporate communications within the biotechnology industry.